Literature DB >> 10841243

A randomized trial comparing heparin initiation 6 h or 24 h after pacemaker or defibrillator implantation.

G F Michaud1, F Pelosi, M D Noble, B P Knight, F Morady, S A Strickberger.   

Abstract

OBJECTIVES: The purpose of this randomized study was to evaluate the prevalence of pocket hematomas in patients treated with heparin 6 h or 24 h after pacemaker or defibrillator implantation.
BACKGROUND: The risks of pocket hematoma and need for evacuation after device implantation have not been defined in patients who require anticoagulation.
METHODS: Forty-nine consecutive patients with an indication for anticoagulation with heparin after implantable defibrillator or pacemaker implantation were randomized to receive intravenous heparin either 6 h (n = 26) or 24 h (n = 23) postoperatively. Both groups also received warfarin on a daily basis starting the evening of surgery. Twenty-eight patients who received postoperative warfarin alone and 115 patients who did not receive anticoagulation were followed up in a study registry.
RESULTS: A pocket hematoma developed in 6 of 26 patients (22%) who were treated with intravenous heparin 6 h postoperatively, as compared with 4 of 23 patients (17%) who were treated with intravenous heparin 24 h postoperatively (p = 0.7). In total, a pocket hematoma developed in 10 of 49 patients (20%) treated with heparin, 1 of 28 patients (4%) treated with warfarin alone and 2 of 115 (2%) patients who received no anticoagulation (p < 0.001).
CONCLUSIONS: Intravenous heparin initiation 6 h or 24 h after pacemaker or defibrillator implantation is associated with a 20% prevalence of pocket hematoma formation. Warfarin therapy or no anticoagulation is associated with only a 2% to 4% risk of pocket hematoma formation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10841243     DOI: 10.1016/s0735-1097(00)00633-1

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  12 in total

Review 1.  Meta-analysis of bleeding complications associated with cardiac rhythm device implantation.

Authors:  Michael L Bernard; Matthew Shotwell; Paul J Nietert; Michael R Gold
Journal:  Circ Arrhythm Electrophysiol       Date:  2012-04-24

Review 2.  [Strategies for the avoidance and treatment of complications during pacemaker implantation].

Authors:  C Kolb
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2007-12

3.  Association of Uninterrupted Oral Anticoagulation During Cardiac Device Implantation with Pocket Hematoma.

Authors:  Brittany L Melton; Patricia A Howard; Abby Goerdt; Jessica Casey
Journal:  Hosp Pharm       Date:  2015-10-14

4.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.

Authors:  Craig T January; L Samuel Wann; Joseph S Alpert; Hugh Calkins; Joaquin E Cigarroa; Joseph C Cleveland; Jamie B Conti; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Katherine T Murray; Ralph L Sacco; William G Stevenson; Patrick J Tchou; Cynthia M Tracy; Clyde W Yancy
Journal:  Circulation       Date:  2014-03-28       Impact factor: 29.690

5.  The frequency and incremental cost of major complications among medicare beneficiaries receiving implantable cardioverter-defibrillators.

Authors:  Matthew R Reynolds; David J Cohen; Aaron D Kugelmass; Phillip P Brown; Edmund R Becker; Steven D Culler; April W Simon
Journal:  J Am Coll Cardiol       Date:  2006-05-30       Impact factor: 24.094

6.  Chronic kidney disease is an independent predictor of pocket hematoma after pacemaker and defibrillator implantation.

Authors:  Imdad Ahmed; Elie Gertner; William B Nelson; Chad M House; Dennis W X Zhu
Journal:  J Interv Card Electrophysiol       Date:  2010-10-13       Impact factor: 1.900

7.  Periprocedural management of anticoagulation and antiplatelet therapies in patients undergoing electrophysiologic procedures.

Authors:  Jordana Kron; Daniel Alexander; Mark A Wood
Journal:  Curr Treat Options Cardiovasc Med       Date:  2009-10

8.  Pacemaker Implantation in Elderly Patients: Safety of Various Regimens of Anticoagulant Therapy.

Authors:  Denis Terekhov; Valeriy Agapov; Kirill Kulikov; Svetlana Zadorozhnaya; Vasiliy Samitin; Vladimir Maslyakov
Journal:  J Atr Fibrillation       Date:  2017-02-28

9.  Incidence of pocket hematoma after electrophysiological device placement: dual antiplatelet therapy versus low-molecular-weight heparin regimen.

Authors:  Yan Chen; Yun-Tao Li; Ming-Dong Gao; Ze-Chun Zeng; Jin-Rong Zhang; Hong-Liang Cong; Yin Liu; Ru Zhao; Le-Feng Wang; Xin-Cun Yang; Kang Meng
Journal:  J Geriatr Cardiol       Date:  2014-09       Impact factor: 3.327

10.  Preparation for pacemaker or implantable cardiac defibrillator implants in patients with high risk of thrombo-embolic events: oral anticoagulation or bridging with intravenous heparin? A prospective randomized trial.

Authors:  Jose M Tolosana; Paola Berne; Lluis Mont; Magda Heras; Antonio Berruezo; Joan Monteagudo; David Tamborero; Begoña Benito; Josep Brugada
Journal:  Eur Heart J       Date:  2009-05-31       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.